Back to School 2020
Oxford’s Landray wants RECOVERY-type trials to go well beyond COVID-19: a BioCentury audio interview
The co-creator of the U.K.’s adaptive platform trial sees uses in multiple other chronic diseases, public health priorities
The co-creator of the U.K.’s adaptive platform trial sees uses in multiple other chronic diseases and public health priorities
Oxford University’s Martin Landray, one of the two initiators of the U.K.’s RECOVERY trial, said while the first consideration in designing the adaptive platform trial was to find a cure for COVID-19 as fast as possible, the second was to create a template that might spur activity in other public health diseases where drug development has faltered.
Landray, professor of medicine and epidemiology, created the RECOVERY trial with Oxford colleague Peter Horby. The trial, which recruited over 12,000 patients, produced three results in the first 100 days and continues to test other therapies for COVID-19.
Landray spoke to BioCentury for the Back to School audio interview series with industry leaders, and discussed his considerations in creating the trial, the advantages of the design that helped generate actionable data so fast, and where else these types of master protocol adaptive